RE: Scared to look13 Oct 2022 20:08
It can't be a SNG because its 2 'on the go' compounds haven't been in drug trials yet - let alone failed a trial. Unlike SNG. SAR idoesn't have a compound being trialled - therefore there is nothing that can fail. That also means SAR is a long way off generating revenue - in the past there was the HNW - but as has been pointed out - at least once - there is every possibility the HNW (who could easily be one of us or a group of us) used what they were given to trade and play with the sp.
That aside, in comparison to SNG, SAR is in a healthier position. Although the value of the sp is down to estimates of eventual, positive outcomes - I guess the more you know about pharma and drugs the more accurately you can make that estimate. Thats why its good if an institution buys in - because you can see what kind of call they made - but... I'm rambling...just to say this is no Synairgen and while the sp might sink a bit - and I guess cash/fundraise issues are in some people's minds - the sp might also rise. Depends what you think of the compounds and their chances.